In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Eric A. Adams, the CEO of InMed Pharmaceuticals, the Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Max and Eric discuss Cannabinol (CBN), the minor cannabinoid at the heart of InMed’s programs, why the company chose it and the advantages it may have over cannabiodiol (CBD) and tetrahydrocannabinol (THC).
InMed presents Phase 2 clinical study results at 12th World Congress on Itch
At the 12th World Congress on Itch (WCI), held in Miami on November 5-7, 2023, InMed’s Senior VP, Clinical and Regulatory Affairs, Alexandra Mancini presented